Kronos Bio
Latest round
- Series A
Last raised
- Jul 2019
Total raised
- $123M
Investors
- 8
About Kronos Bio
Founded in 2017 and headquartered in San Mateo, US, Kronos Bio, Inc. specializes in targeting gene regulation to create cancer treatments.157 million shares at USD 19 per share on the Nasdaq. The CEO is Norbert Bischofberger. Kronos Bio, Inc. develops a range of cancer therapies aimed at inhibiting specific cellular pathways involved in tumor growth. The company's core offerings focus on innovative drug candidates that target gene transcription and regulatory mechanisms, which are critical in cancer biology. Their products are marketed worldwide, catering to oncologists, hospitals, and research institutions that seek effective cancer treatment options.
Who invested in Kronos Bio
8 investors across 2 rounds
See all investors in Kronos Bio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Kronos Bio
Who invested in Kronos Bio?
Kronos Bio has 8 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Kronos Bio raised?
Kronos Bio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Kronos Bio last raise money?
Kronos Bio's most recent round on record is a Series A, in Jul 2019.
What does Kronos Bio do?
Founded in 2017 and headquartered in San Mateo, US, Kronos Bio, Inc.
Where is Kronos Bio headquartered?
Kronos Bio is headquartered in San Mateo, US.
Which VCs invest in companies like Kronos Bio?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Kronos Bio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Kronos Bio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.